Effect and mechanism of Zuojin Wan on reversing cetuximab resistance in <italic style="font-style: italic">KRAS</italic> mutant colorectal cancer

ZHOU Jing; WEI Zhenzhen; PU Yunzhou; LI Ling; ZHU Huirong; JI Qing; LI Hongshan

doi:10.16305/j.1007-1334.2023.2210064

您当前的位置：

首页 >

文章列表页 >

Effect and mechanism of Zuojin Wan on reversing cetuximab resistance in KRAS mutant colorectal cancer

更新时间：2023-05-16

- Effect and mechanism of Zuojin Wan on reversing cetuximab resistance in KRAS mutant colorectal cancer
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 5, Pages: 37-45(2023)
- 作者机构：
  
  1.浙江省宁波市第二医院中西医结合肝病科（浙江宁波 315010）
  2.上海中医药大学附属曙光医院肿瘤科（上海 201203）
  3.上海市第一人民医院嘉定分院实验医学中心（上海 201803）
  4.浙江省消化系统肿瘤诊治及研究重点实验室（浙江宁波 315010）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2210064
  CLC：
扫描看全文
周晶,卫真真,浦匀舟,等.左金丸逆转KRAS突变型大肠癌西妥昔单抗耐药的作用机制研究[J].上海中医药杂志,2023,57(5):37-45.

ZHOU Jing,WEI Zhenzhen,PU Yunzhou,et al.Effect and mechanism of Zuojin Wan on reversing cetuximab resistance in KRAS mutant colorectal cancer[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):37-45.
周晶,卫真真,浦匀舟,等.左金丸逆转KRAS突变型大肠癌西妥昔单抗耐药的作用机制研究[J].上海中医药杂志,2023,57(5):37-45. DOI： 10.16305/j.1007-1334.2023.2210064.

ZHOU Jing,WEI Zhenzhen,PU Yunzhou,et al.Effect and mechanism of Zuojin Wan on reversing cetuximab resistance in KRAS mutant colorectal cancer[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):37-45. DOI： 10.16305/j.1007-1334.2023.2210064.

摘要

目的,2,探讨左金丸（ZJW）对,KRAS,突变型大肠癌西妥昔单抗（CET）耐药的逆转作用及其机制。,方法,2,①常规培养,KRAS,突变人结肠癌细胞HCT116，通过细胞增殖率（CCK-8法检测）确定ZJW无毒剂量（即10 mg·L,-1,），观察ZJW、CET的协同效应（ZJW 10 mg·L,-1,与CET 100、200 mg·L,-1,具有协同效应，本研究选择CET 100 mg·L,-1,进行后续实验）。将处于对数生长期的HCT116细胞分为对照组、CET 100 mg·L,-1,组（CET组）、ZJW 10 mg·L,-1,组（ZJW组）、CET 100 mg·L,-1,+ ZJW 10 mg·L,-1,组（ZJW+CET组），作用48 h；采用流式细胞仪分析细胞周期和凋亡情况，Western blot法检测细胞中核因子-κB p65（NF-κB p56）、B淋巴细胞瘤-2（Bcl-2）蛋白表达情况，免疫荧光法检测细胞中NF-κB p65、磷酸化核因子-κB p65（p-NF-κB p65）、半胱氨酸天冬氨酸蛋白酶-3（Caspase-3）表达情况，实时荧光定量逆转录聚合酶链式反应（RT-qPCR）法检测细胞中,NF,-,κB,p65,、,Bcl,-,2,、,Caspase,-,3, mRNA表达情况。②将HCT116细胞皮下注射于裸鼠腋下，建立大肠癌皮下移植瘤模型，然后将16只裸鼠随机分为对照组（PBS灌胃）、CET组（CET尾静脉注射，15 mg·kg,-1,）、ZJW+CET组（CET尾静脉注射，15 mg·kg,-1,；ZJW灌胃，2 055 mg·kg,-1,）、ZJW组（ZJW灌胃，2 055 mg·kg,-1,），每组4只，连续干预28 d，绘制肿瘤生长图，28 d后剥离肿瘤组织，RT-qPCR法检测皮下移植瘤组织,NF,-,κB p65,、,Bcl,-,2,、,Caspase,-,3 ,mRNA表达情况。,结果,2,①ZJW在HCT116细胞中的IC,10,为10.71 mg·L,-1,；CET抑制HCT116增殖的IC,50,为578.6 mg·L,-1,，与10 mg·L,-1 ,左金丸联合使用时IC,50,值降低为231.3 mg·L,-1,；CET 100、200 mg·L,-1,与ZJW 5、10 mg·L,-1,联合使用时，药物联合指数（CI）,<,1。②与对照组相比，ZJW组、ZJW+CET组细胞S期比例、早期凋亡率升高（,P,<,0.05）；与CET组相比，ZJW组细胞S期比例、早期凋亡率升高（,P,<,0.05）；与ZJW组相比，ZJW+CET组S期细胞比例、早期凋亡率升高（,P,<,0.05）。③与对照组比较，CET组、ZJW组细胞中Bcl-2表达降低（,P,<,0.05），ZJW组细胞中Caspase-3表达升高（,P,<,0.05），ZJW+CET组细胞Bcl-2、NF-κB p65、p-NF-κB p65表达降低（,P,<,0.05）；与CET组相比，ZJW+CET组细胞中Bcl-2、NF-κB p65、p-NF-κB p65表达降低（,P,<,0.05），Caspase-3表达升高（,P,<,0.05）；与ZJW组相比，ZJW+CET组细胞Bcl-2、NF-κB p65、p-NF-κB p65表达降低（,P,<,0.05），Caspase-3表达升高（,P,<,0.05）。④与对照组相比，ZJW组、ZJW+CET组细胞,Bcl,-,2,、,NF,-,κB,p65 ,mRNA表达降低（,P,<,0.05）；与CET组相比，ZJW组、ZJW+CET组细胞,Bcl,-,2,、,NF,-,κB,p65, mRNA表达降低（,P,<,0.05）；与ZJW组相比，ZJW+CET组细胞,Bcl,-,2,、,NF,-,κB p65 ,mRNA表达降低（,P,<,0.05）。⑤相较于对照组、CET组，ZJW组、ZJW+CET组裸鼠瘤体生长较为缓慢。给药28 d后剥离瘤体，与对照组相比，ZJW组、ZJW+CET组裸鼠皮下移植瘤体积缩小（,P,<,0.05）；与CET组相比，ZJW、ZJW+CET组裸鼠皮下移植瘤体积缩小（,P,<,0.05）；与ZJW组比较，ZJW+CET组裸鼠皮下移植瘤体积缩小（,P,<,0.05）。⑥与对照组相比，ZJW组、ZJW+CET组瘤体组织中,NF,-,κB p65,、,Bcl,-,2 ,mRNA表达降低，,Caspase,-,3 ,mRNA表达升高（,P,<,0.05）；与CET组相比，ZJW组瘤体组织中,Caspase,-,3 ,mRNA表达升高（,P,<,0.05）；与ZJW组相比，ZJW+CET组瘤体组织中,Caspase,-,3 ,mRNA表达升高（,P,<,0.05）。,结论,2,ZJW可通过抑制细胞增殖、阻滞细胞周期、促进细胞凋亡等途径逆转,KRAS,突变大肠癌细胞对CET的耐药，继而抑制大肠癌生长，其机制可能与调控NF-κB/Bcl-2/Caspase-3通路相关。

Abstract

Objective,2,To investigate the effect and mechanism of Zuojin Wan （ZJW） on reversing the resistance to cetuximab （CET） in ,KRAS, mutation colorectal cancer.,Methods,2,①,KRAS, mutant human colon cancer cells HCT116 were cultured and the non-toxic dose （10 mg·L,-1,） of ZJW was determined by cell proliferation rate （CCK-8 assay）. The synergistic effect of ZJW and CET was observed （Due to the synergistic effect between ZJW 10 mg·L,-1, and CET 100 and 200 mg·L,-1,， CET 100 mg·L,-1, was selected for follow-up experiment in this study）. HCT116 cells in logarithmic growth phase were divided into control group， CET 100 mg·L,-1, （CET group）， ZJW 10 mg·L,-1, （ZJW group）， CET 100 mg·L,-1,+ ZJW 10 mg·L,-1, （ZJW+CET group）， and were treated for 48 h. The cell cycle and apoptosis were analyzed by flow cytometry， and the expressions of nuclear factor-κB p65 （NF-κB p65） and B lymphocytoma-2 （Bcl-2） were detected by Western blot. The expressions of NF-κB p65， phosphorylated nuclear factor-κB p65（p-NF-κB p65） and cysteine aspartic protease-3 （Caspase-3） were detected by immunofluorescence， and the mRNA expressions of ,NF,-,κB p65， Bcl,-,2 ,and ,Caspase,-,3, were detected by real-time fluorescence quantitative reverse transcription polymerase chain reaction （RT-qPCR）. ②HCT116 cells were injected subcutaneously into the axilla of nude mice to establish a subcutaneously transplanted tumor model of colorectal cancer， and then 16 nude mice were randomly divided into control group （PBS gavage， ,n,=4）， CET group （CET caudal vein injection， 15 mg·kg,-1,，, n,=4）， ZJW+CET group （CET caudal vein injection， 15 mg·kg,-1,； ZJW gavage， 2 055 mg·kg,-1,， ,n,=4）， and ZJW group （ZJW gavage， 2 055 mg·kg,-1,， ,n,=4）. Intervention were given continuously for 28 d， and tumor growth curves were plotted. The tumor tissue was stripped after 28 d， and the mRNA expressions of ,NF,-,κB p65,， ,Bcl,-,2,， ,Caspase,-,3, in subcutaneous transplanted tumor tissues were detected by RT-qPCR.,Results,2,①The IC,10, value of ZJW in HCT116 cells was 10.71 mg·L,-1,； The IC,50, value of CET inhibiting the proliferation of HCT116 was 578.6 mg·L,-1,， and the IC,50, value decreased to 231.3 mg·L,-1, with the combined use of 10 mg·L,-1, ZJW. The drug combination index （CI） value was less than 1 when CET 100 and 200 mg·L,-1, was used together with ZJW 5 and 10 mg·L,-1,. ②Compared with those in control group， the S-phase proportion and early apoptosis rate of cells in ZJW and ZJW+CET groups increased （,P,<,0.05）. Compared with those in CET group， S-phase proportion and early apoptosis rate of cells in ZJW group increased （,P,<,0.05）. Compared with those in ZJW group， S-phase cell proportion and early apoptosis rate in ZJW+CET group increased （,P,<,0.05）. ③Compared with those in control group， the expression of Bcl-2 in CET and ZJW groups decreased （,P,<,0.05）， the expression of Caspase-3 in ZJW group increased （,P,<,0.05）， and the expressions of Bcl-2， NF-κB p65 and p-NF-κB p65 in ZJW+CET group decreased （,P,<,0.05）. Compared with those in CET group， the expressions of Bcl-2， NF-κB p65 and p-NF-κB p65 in ZJW+CET group decreased （,P,<,0.05）， while the expression of Caspase-3 increased （,P,<,0.05）. Compared with those in ZJW group， the expressions of Bcl-2， NF-κB p65 and p-NF-κB p65 in ZJW+CET group decreased （,P,<,0.05）， while the expression of Caspase-3 increased （,P,<,0.05）. ④ Compared with those in control group， the mRNA expressions of ,Bcl,-,2, and ,NF,-,κB p65, in ZJW and ZJW+CET groups decreased （,P,<,0.05）. Compared with those in CET group， the mRNA expressions of ,Bcl,-,2, and, NF,-,κB p65, in ZJW and ZJW+CET groups decreased （,P,<,0.05）. Compared with those in ZJW group， mRNA expressions of ,Bcl,-,2, and ,NF,-,κB p65, in ZJW+CET group decreased （,P,<,0.05）. ⑤The tumor growth of nude mice in CET gtroup， ZJW group and ZJW+CET group was slower than that in control group. The tumors were stripped after 28 d of administration， and the volume of subcutaneous transplanted tumors in nude mice in ZJW group and ZJW+CET group was smaller than that in control group （,P,<,0.05）. The volume of subcutaneous transplanted tumors in nude mice in ZJW and ZJW+CET groups was smaller than that in CET group （,P,<,0.05）. The volume of subcutaneous transplanted tumors in nude mice in ZJW+CET group was smaller than that in ZJW group （,P,<,0.05）. ⑥Compared with those in control group， the mRNA expressions of ,NF,-,κB p65 ,and ,Bcl,-,2, were lower and the mRNA expression of ,Caspase,-,3 ,was higher than that in CET Group in ZJW and ZJW+CET groups （,P,<,0.05）. The mRNA expression of ,Caspase,-,3, in ZJW group was higher （,P,<,0.05）. Compared with that in ZJW group， the mRNA expression of ,Caspase,-,3, in tumor tissues in ZJW+CET group was higher than that in ZJW group（,P,<,0.05）.,Conclusions,2,ZJW can reverse the resistance to CET in ,KRAS, mutant colorectal cancer by inhibiting cell proliferation， blocking cell cycle and promoting cell apoptosis， and subsequently inhibiting the growth of colorectal cancer. The mechanism may be related to the regulation of NF-κB/Bcl-2/Caspase-3 pathway.

关键词

大肠癌左金丸靶向治疗耐药中药研究作用机制

Keywords

colorectal cancerZuojin Wantargeted therapydrug resistancetraditional Chinese herbal medicine researchmechanism of action

references

SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71： 209-249.

SIEGEL R L， MILLER K D， JEMAL A. Cancer statistics， 2020［J］. CA Cancer J Clin， 2020， 70： 7-30.

STINTZING S， MODEST D P， ROSSIUS L， et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer （FIRE-3）： a post-hoc analysis of tumourdynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial［J］. Lancet Oncol， 2016， 17（10）： 1426-1434.

CREMOLINI C， ROSSINI D， DELL'AQUILA E， et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan： a phase 2 single-arm clinical trial［J］. JAMA Oncol， 2019， 5（3）： 343-350.

SUI H， PAN S F， FENG Y， et al. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway［J］. BMC Complement Altern Med， 2014， 14： 279.

李艳英，黄能听，韩馥蔓，等. 左金丸的古代文献分析［J］. 中国实验方剂学杂志，2022， 28（12）： 39-47.

张勇，周勇锋，罗璐. 麦门冬汤联合左金丸治疗食管癌术后反流性食管炎的临床观察［J］.世界中西医结合杂志，2020， 15（6）： 1096-1099， 1103.

TANG Q F， SUN J， YU H， et al. The Zuo Jin Wan Formula induces mitochondrial apoptosis of cisplatin-resistant gastric cancer cells via cofilin-1［J/OL］. Evid Based Complement Alternat Med， 2016： 8203789［2022-10-08］. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC5107242/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107242/.

SUN M Y， WANG D D， SUN J， et al. The Zuo Jin Wan Formula increases chemosensitivity of human primary gastric cancer cells by AKT mediated mitochondrial translocation of cofilin-1［J］. Chin J Nat Med， 2019， 17（3）： 198-208.

刘艳，孙健. 左金丸调控AMPK/mTOR通路介导的自噬途径逆转胃癌耐药机制研究［J］.重庆医学，2022， 51（1）： 6-11.

GAPTULBAROVA K A， TSYGANOV M M， PEVZNER A M， et al. NF-κB as a potential prognostic marker and a candidate for targeted therapy of cancer［J］. Exp Oncol， 2020， 42（4）： 263-269.

JIANG N， DONG X P， ZHANG S L， et al. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes［J］. Mol Med Rep， 2016， 13（1）： 153-159.

FANG X J， JIANG H， ZHU Y Q， et al. Doxorubicin induces drug resistance and expression of the novel CD44st via NF-κB in human breast cancer MCF-7 cells［J］. Oncol Rep， 2014， 31（6）： 2735-2742.

TIAN M， TIAN D， QIAO X， et al. Modulation of Myb-induced NF-κB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors［J］. J Cell Physiol， 2019， 234（11）： 21126-21134.

DOLCET X， LOBET D， PALLARES J， et al. NF-κB in development and progression of human cancer［J］. Virchows Arch， 2005， 446（5）： 475-482.

WILLIS S， DAY C L， HIMDS M G， et al. The Bcl-2-regulated apoptotic pathway［J］. J Cell Sci， 2003，116（Pt 20）： 4053-4056.

CHEN C， EDELSTEIN L C， GELINAS C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x（L）［J］. Mol Cell Biol， 2000， 20（8）： 2687-2695.

TAMATANI M， CHE Y H， MATSUZAKI H， et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF kappaB activation in primary hippocampal neurons［J］. J Biol Chem， 1999， 274（13）： 8531-8538.

RICCA A， BIROCCIO A， DEL BUFALO D， et al. Bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7（ADR） breast-cancer cells［J］. Int J Cancer， 2000， 86（2）： 188-196.

ASLAN A， GOK O， EEMAN O， et al. Ellagic acid impedes carbontetrachloride-induced liver damage in rats through suppression of NF-κB， Bcl-2 and regulating Nrf-2 and caspase pathway［J］. Biomed Pharmacother， 2018， 105： 662-669.

CHEN P M， WU T C， WANG Y C， et al. Activation of NF-κB by SOD2 promotes the aggressiveness of lung adenocarcinoma by modulating NKX2-1-mediated IKKβ expression［J］. Carcinogenesis， 2013， 34（11）： 2655-2663.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Jianpi Jiedu Formula to inhibit epithelial mesenchymal transition of colorectal cancer through Hippo signaling pathway

Resistance mechanism of EGFR targeted therapy for colorectal cancer and research progress of traditional Chinese herbal medicines

Mechanism of Yucan Granules improving podocyte damage and treating diabetic nephropathy

Mechanism of Huangqi Decoction against liver fibrosis by network pharmacological analysis combined with related cell experiment

Network pharmacology and molecular docking study on the mechanism of action of puerarin for Alzheimer's disease

Related Author

No data

Related Institution

Department of Medical Oncology and Cancer Institute， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology/Institute of Oncology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology I， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Nephrology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Interdisciplinary Integrative Medicine Research， Shanghai University of Traditional Chinese Medicine

⁰

Effect and mechanism of Zuojin Wan on reversing cetuximab resistance in KRAS mutant colorectal cancer

DOI：10.16305/j.1007-1334.2023.2210064

摘要

Abstract

关键词

Keywords

references